<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05112718</url>
  </required_header>
  <id_info>
    <org_study_id>420/20-09-2019</org_study_id>
    <nct_id>NCT05112718</nct_id>
  </id_info>
  <brief_title>Platelet Rich Plasma in Women With Urinary Incontinence</brief_title>
  <official_title>The Use of Platelet Rich Plasma (PRP) as a Treatment of the Female Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stress urinary incontinence (SUI) is defined as involuntary loss of urine on effort or&#xD;
      physical exertion or on sneezing or coughing. Platelet-rich plasma (PRP) is an autologous&#xD;
      solution of human plasma containing various growth factors witch enhance regeneration and&#xD;
      healing process. The aim of this study is to evaluate the efficacy and safety of PRP in the&#xD;
      treatment of the female SUI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stress urinary incontinence symptoms</measure>
    <time_frame>6-12 months</time_frame>
    <description>International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms Modules (ICIQ-FLUTS) Number of items: 12&#xD;
Question items:&#xD;
Nocturia,Urgency, Bladder pain, Frequency, Hesitancy, Straining, Intermittency, Urge urinary incontinence, Frequency of urinary incontinence, Stress urinary incontinence, Unexplained urinary incontinence, Nocturnal enuresis&#xD;
Completion time: 4-5 minutes&#xD;
Scoring:&#xD;
0-16 filling symptoms subscale 0-12 voiding symptoms subscale 0-20 incontinence symptoms subscale 0-48 where all subscale scores are added. Bother scales are not incorporated in the overall score but indicate impact of individual symptoms for the patient&#xD;
Higher scores indicate greater impact of individual symptoms for the patient.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of urinary incontinence on the quality of life</measure>
    <time_frame>6-12 months</time_frame>
    <description>King's Health Questionnaire (KHQ)&#xD;
Description: The KHQ is an assessment of health-related quality of life related to a specific condition.&#xD;
Format: 21 items about urinary tract symptoms yield scores in 9 domains (general health perception, incontinence impact, role limitations, physical limitations, social limitations, personal relationships, emotions, sleep/energy &amp; severity of symptoms).&#xD;
Scoring: Each item is rated using a 4 or 5 points likert scale. Domain scores range from 0 (best) to 100 (worst). There are 2 single-item domains (general health perceptions, and incontinence impact) and the severity of symptoms domain is scored using a scale from 0 (best) to 30 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of urine loss (1-hr pad test)</measure>
    <time_frame>6-12 months</time_frame>
    <description>One-hour pad test standardized by International Continence Society (ICS):&#xD;
started by putting one pre-weighted pad,&#xD;
patient drinks 500 ml in &lt;15 min- then sits or rests,&#xD;
patient walks for 30 min,&#xD;
patient performs the following activities: standing up from sitting, coughing vigorously, running on the spot for 1 min, bending to pick up an object from the floor, and washing hands in running water for 1min&#xD;
the total amount of urine leaked is determined by weighing the pad.&#xD;
Interpretation:&#xD;
The upper limit of weight increase for the 1-hr test in continent women is 1.4 grams.&#xD;
A weight gain of less than 1.4 g during 1-hr test could be a result of sweating or vaginal discharge.&#xD;
An increase of 1-10 g is classified as representing mild incontinence, 11-50 g moderate and &gt;50 g severe incontinence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of discomfort during injections (VAS score)</measure>
    <time_frame>6-12 months</time_frame>
    <description>The visual analog scale (VAS) is pain rating scale. Scores are based on self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-&quot;no pain&quot; on the left end (0 cm) of the scale and the &quot;worst pain&quot; on the right end of the scale (10 cm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement</measure>
    <time_frame>6-12 months</time_frame>
    <description>The Patient Global Impression of Improvement (PGI-I) is a validated generic tool for assessment of the over-all improvement or deterioration that the patient may experience following the treatment.&#xD;
The PGI-I is a transition scale that is a single question asking the patient to rate their urinary tract condition now, as compared with how it was prior to before beginning treatment on a scale from 1. Very much better to 7. Very much worse.&#xD;
Therefore, lower values correlate with increased satisfaction.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients who receive PRP injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The patients who receive normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Rich Plasma Injections</intervention_name>
    <description>PRP injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).&#xD;
The participants will receive 2 PRP injections at 4-6-week intervals. Xylocaine gel 2% is applied to the distal anterior vaginal wall 20 minutes before injections.</description>
    <arm_group_label>Platelet Rich Plasma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline Injections</intervention_name>
    <description>Normal saline injected into 9 sites of the distal anterior one-third of the vagina using a small 30-gauge needle. The injections were performed at 10, 12 and 2 o'clock in 3 different levels of the urethra 1-2 cm apart (distal, mid and proximal).&#xD;
The participants will receive 2 injections at 4-6-week intervals.</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult women with stress urinary incontinence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy,&#xD;
&#xD;
          -  history of active malignant pathology,&#xD;
&#xD;
          -  mental disorders making them unable to give consent,&#xD;
&#xD;
          -  undiagnosed abnormal uterine bleeding,&#xD;
&#xD;
          -  genitourinary fistula,&#xD;
&#xD;
          -  anti-incontinence surgery,&#xD;
&#xD;
          -  pelvic organ prolapse stage &gt; 2 according to POP-Q system&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stavros Athanasiou, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National and Kapodistrian University of Athens</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stavros Athanasiou, Professor</last_name>
    <phone>+306944478555</phone>
    <email>stavros.athanasiou@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urogynecological Unit of Alexandra Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stavros Athanasiou, Prof.</last_name>
      <phone>+306944478555</phone>
      <email>stavros.athanasiou@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Themos Grigoriadis, As. Prof.</last_name>
      <phone>+306948741306</phone>
      <email>tgregos@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stavros Athanasiou, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Themos Grigoriadis, As. Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christos Kalantzis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Dawood AS, Salem HA. Current clinical applications of platelet-rich plasma in various gynecological disorders: An appraisal of theory and practice. Clin Exp Reprod Med. 2018 Jun;45(2):67-74. doi: 10.5653/cerm.2018.45.2.67. Epub 2018 Jun 29. Review.</citation>
    <PMID>29984206</PMID>
  </reference>
  <reference>
    <citation>Alves R, Grimalt R. A Review of Platelet-Rich Plasma: History, Biology, Mechanism of Action, and Classification. Skin Appendage Disord. 2018 Jan;4(1):18-24. doi: 10.1159/000477353. Epub 2017 Jul 6. Review.</citation>
    <PMID>29457008</PMID>
  </reference>
  <reference>
    <citation>Schreiber Pedersen L, Lose G, HÃ¸ybye MT, Elsner S, Waldmann A, Rudnicki M. Prevalence of urinary incontinence among women and analysis of potential risk factors in Germany and Denmark. Acta Obstet Gynecol Scand. 2017 Aug;96(8):939-948. doi: 10.1111/aogs.13149. Epub 2017 May 20.</citation>
    <PMID>28401541</PMID>
  </reference>
  <reference>
    <citation>Behnia-Willison F, Nguyen TTT, Norbury AJ, Mohamadi B, Salvatore S, Lam A. Promising impact of platelet rich plasma and carbon dioxide laser for stress urinary incontinence. Eur J Obstet Gynecol Reprod Biol X. 2019 Oct 22;5:100099. doi: 10.1016/j.eurox.2019.100099. eCollection 2020 Jan.</citation>
    <PMID>32021973</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Themos Grigoriadis</investigator_full_name>
    <investigator_title>Associate Professor of Gynecology</investigator_title>
  </responsible_party>
  <keyword>incontinence</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>stress urinary incontinence</keyword>
  <keyword>platelet rich plasma</keyword>
  <keyword>PRP,</keyword>
  <keyword>outpatient treatment</keyword>
  <keyword>nonsurgical treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

